SCHEMBL1551003

SCHEMBL1551003

O=C(O)COc1ccc(C#Cc2ccccc2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 6/20 1.00
ALOX15 P16050 1/20 0.70
PTPN7 P35236 2/20 0.61
ALDH1A1 P00352 2/20 0.61
MEN1 O00255 1/20 0.61
MAPT P10636 1/20 0.61
KMT2A Q03164 1/20 0.61
PTPN12 Q05209 1/20 0.61
PTGDR2 Q9Y5Y4 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.53
FFAR4 Q5NUL3 1/20 0.53
PPARG P37231 2/20 0.53
PPARD Q03181 1/20 0.53
PPARA Q07869 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1550206 0.87 FFAR1 (0.77) FFAR1ALOX15PTPN7ALDH1A1MEN1
SCHEMBL1551412 0.85 FFAR1 (1.00) FFAR1ALOX15PTPN7ALDH1A1MEN1
SCHEMBL1550667 0.85 FFAR1 (0.74) FFAR1ALOX15ALDH1A1MAPTSMN1; SMN2
SCHEMBL1778144 0.84 FFAR1 (0.71) FFAR1ALOX15PTPN7ALDH1A1MEN1
SCHEMBL1551462 0.84 FFAR1 (1.00) FFAR1ALOX15PTPN7ALDH1A1MEN1
SCHEMBL1550243 0.84 FFAR1 (1.00) FFAR1ALOX15PTGDR2SMN1; SMN2FFAR4
SCHEMBL1551092 0.84 FFAR1 (0.72) FFAR1ALOX15PTPN7ALDH1A1MEN1
SCHEMBL8127 0.83 ALOX15 (1.00) FFAR1ALOX15PTPN7ALDH1A1MEN1
SCHEMBL1318870 0.83 ALOX15 (1.00) FFAR1ALOX15PTPN7ALDH1A1MEN1
SCHEMBL339492 0.83 ALOX15 (0.81) FFAR1ALOX15PTPN7ALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8586607-B2 Compounds for the treatment of metabolic diseases SYDDANSK UNIVERSITET (DK) 2013-11-19 US claimed
EP-2313360-B1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES UNIV SYDDANSK (DK) 2012-09-05 EP claimed
US-20110152315-A1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES SYDDANSK UNIVERSITET 2011-06-23 US claimed
EP-2313360-A1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES Syddansk Universitet (DK) 2011-04-27 EP claimed
WO-2010012650-A1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES SYDDANSK UNIVERSITET (DK) 2010-02-04 WO claimed
WO-1999029640-A2 COMPOSITIONS AND METHODS FOR MODULATING THE ACTIVITY OF FIBROBLAST GROWTH FACTOR EISAI CO., LTD. (JP) 1999-06-17 WO claimed
US-8586607-B2 Compounds for the treatment of metabolic diseases SYDDANSK UNIVERSITET (DK) 2013-11-19 US disclosed
US-8586607-B2 Compounds for the treatment of metabolic diseases SYDDANSK UNIVERSITET (DK) 2013-11-19 US disclosed
EP-2313360-B1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES UNIV SYDDANSK (DK) 2012-09-05 EP disclosed
EP-2313360-B1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES UNIV SYDDANSK (DK) 2012-09-05 EP disclosed
US-20110152315-A1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES SYDDANSK UNIVERSITET 2011-06-23 US disclosed
US-20110152315-A1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES SYDDANSK UNIVERSITET 2011-06-23 US disclosed
EP-2313360-A1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES Syddansk Universitet (DK) 2011-04-27 EP disclosed
WO-2010012650-A1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES SYDDANSK UNIVERSITET (DK) 2010-02-04 WO disclosed
WO-2010012650-A1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES SYDDANSK UNIVERSITET (DK) 2010-02-04 WO disclosed
WO-1999029640-A2 COMPOSITIONS AND METHODS FOR MODULATING THE ACTIVITY OF FIBROBLAST GROWTH FACTOR EISAI CO., LTD. (JP) 1999-06-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110152315-A1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES GPR119, INSR, GPR65 FFAR1 6/4885ALOX15 763/4885PTPN7 3883/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.